Skip to main content
Erschienen in:

24.07.2024 | Research

Frequency of and risk factors associated with local recurrence after spinal stereotactic body radiation therapy without surgery

verfasst von: Hidetoshi Shimizu, Yutaro Koide, Shoichi Haimoto, Takahiro Aoyama, Hiroyuki Tachibana, Shingo Hashimoto, Tohru Iwata, Tomoki Kitagawa, Takeshi Kodaira

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to identify factors associated with local recurrence after spinal stereotactic body radiation therapy (SBRT), focusing on patient movement during treatment and tumor characteristics.

Methods

A total of 48 patients who underwent spinal SBRT alone without surgery from August 2017 to October 2022 were evaluated. Logistic regression analysis was conducted to identify factors associated with local recurrence, including patient movement and tumor characteristics such as soft tissue involvement and tumor volume. Patient movement during treatment was measured using cone beam computed tomography before and after irradiation.

Results

Among the included cases, 68.7% and 42.6% had soft tissue involvement and movement exceeding 1 mm, respectively. The median follow-up duration for local recurrence was 11.6 (range: 0.7–44.9) months, whereas the median duration to local recurrence was 6.3 months. Within 12 months, 29.3% of the patients experienced local recurrence, among whom 43.9% moved ≥ 1 mm during treatment, whereas 15.8% did not move. Univariable analysis found that both soft tissue involvement (OR = 10.3, 1.21–87.9; p = 0.033) and patient movement ≥ 1 mm (OR = 5.75, 1.45–22.8; p = 0.013) were associated with local recurrence. Multivariable analysis identified patient movement as an independent prognostic factor for local recurrence (OR = 5.15, 1.06–25.0; p = 0.042).

Conclusion

Our results suggest that patient movement during spinal SBRT was associated with local recurrence, emphasizing the need for better immobilization techniques and shorter delivery times to improve tumor control.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Guninski RS, Cuccia F, Alongi F, Andratschke N, Belka C, Bellut D, Dahele M, Josipovic M, Kroese TE, Mancosu P, Minniti G, Niyazi M, Ricardi U, Munck Af Rosenschold P, Sahgal A, Tsang Y, Verbakel WFAR, Guckenberger M (2024) Efficacy and safety of SBRT for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol 190:109969. https://doi.org/10.1016/j.radonc.2023.109969CrossRefPubMed Guninski RS, Cuccia F, Alongi F, Andratschke N, Belka C, Bellut D, Dahele M, Josipovic M, Kroese TE, Mancosu P, Minniti G, Niyazi M, Ricardi U, Munck Af Rosenschold P, Sahgal A, Tsang Y, Verbakel WFAR, Guckenberger M (2024) Efficacy and safety of SBRT for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol 190:109969. https://​doi.​org/​10.​1016/​j.​radonc.​2023.​109969CrossRefPubMed
6.
Zurück zum Zitat Expert Panel on Radiation Oncology-Bone Metastases, Lo SSM, Lutz ST, Chang EL, Galanopoulos N, Howell DD, Kim EY, Konski AA, Pandit-Taskar ND, Rose PS, Ryu S, Silverman LN, Sloan AE, Van Poznak C (2013) ACR appropriateness Criteria ® spinal bone metastases. J Palliat Med 16:9–19. https://doi.org/10.1089/jpm.2012.0376CrossRef Expert Panel on Radiation Oncology-Bone Metastases, Lo SSM, Lutz ST, Chang EL, Galanopoulos N, Howell DD, Kim EY, Konski AA, Pandit-Taskar ND, Rose PS, Ryu S, Silverman LN, Sloan AE, Van Poznak C (2013) ACR appropriateness Criteria ® spinal bone metastases. J Palliat Med 16:9–19. https://​doi.​org/​10.​1089/​jpm.​2012.​0376CrossRef
7.
Zurück zum Zitat Tseng CL, Soliman H, Myrehaug S, Lee YK, Ruschin M, Atenafu EG, Campbell M, Maralani P, Yang V, Yee A, Sahgal A (2018) Imaging-based outcomes for 24 gy in 2 daily fractions for patients with de novo spinal metastases treated with spine stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 102:499–507. https://doi.org/10.1016/j.ijrobp.2018.06.047CrossRefPubMed Tseng CL, Soliman H, Myrehaug S, Lee YK, Ruschin M, Atenafu EG, Campbell M, Maralani P, Yang V, Yee A, Sahgal A (2018) Imaging-based outcomes for 24 gy in 2 daily fractions for patients with de novo spinal metastases treated with spine stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 102:499–507. https://​doi.​org/​10.​1016/​j.​ijrobp.​2018.​06.​047CrossRefPubMed
9.
Zurück zum Zitat Zeng KL, Sahgal A, Husain ZA, Myrehaug S, Tseng CL, Detsky J, Sarfehnia A, Ruschin M, Campbell M, Foster M, Das S, Lipsman N, Bjarnason GA, Atenafu EG, Maralani PJ, Soliman H (2021) Local control and patterns of failure for Radioresistant spinal metastases following stereotactic body radiotherapy compared to a Radiosensitive reference. J Neurooncol 152:173–182. https://doi.org/10.1007/s11060-020-03691-6CrossRefPubMed Zeng KL, Sahgal A, Husain ZA, Myrehaug S, Tseng CL, Detsky J, Sarfehnia A, Ruschin M, Campbell M, Foster M, Das S, Lipsman N, Bjarnason GA, Atenafu EG, Maralani PJ, Soliman H (2021) Local control and patterns of failure for Radioresistant spinal metastases following stereotactic body radiotherapy compared to a Radiosensitive reference. J Neurooncol 152:173–182. https://​doi.​org/​10.​1007/​s11060-020-03691-6CrossRefPubMed
10.
Zurück zum Zitat Kowalchuk RO, Mullikin TC, Spears GM, Johnson-Tesch BA, Rose PS, Siontis BL, Kun Kim D, Costello BA, Morris JM, Gao RW, Shiraishi S, Lucido JJ, Olivier KR, Owen D, Stish BJ, Waddle MR, Laack NN, Park SS, Brown PD, Merrell KW (2024) Assessment of minimum target dose as a predictor of local failure after spine SBRT. Radiother Oncol 195:110260. https://doi.org/10.1016/j.radonc.2024.110260CrossRefPubMed Kowalchuk RO, Mullikin TC, Spears GM, Johnson-Tesch BA, Rose PS, Siontis BL, Kun Kim D, Costello BA, Morris JM, Gao RW, Shiraishi S, Lucido JJ, Olivier KR, Owen D, Stish BJ, Waddle MR, Laack NN, Park SS, Brown PD, Merrell KW (2024) Assessment of minimum target dose as a predictor of local failure after spine SBRT. Radiother Oncol 195:110260. https://​doi.​org/​10.​1016/​j.​radonc.​2024.​110260CrossRefPubMed
14.
Zurück zum Zitat Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y (2012) International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:e597–e605. https://doi.org/10.1016/j.ijrobp.2012.03.009CrossRefPubMed Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y (2012) International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:e597–e605. https://​doi.​org/​10.​1016/​j.​ijrobp.​2012.​03.​009CrossRefPubMed
15.
Zurück zum Zitat Dunne EM, Sahgal A, Lo SS, Bergman A, Kosztyla R, Dea N, Chang EL, Chang UK, Chao ST, Faruqi S, Ghia AJ, Redmond KJ, Soltys SG, Liu MC (2020) International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol 145:21–29. https://doi.org/10.1016/j.radonc.2019.11.026CrossRefPubMed Dunne EM, Sahgal A, Lo SS, Bergman A, Kosztyla R, Dea N, Chang EL, Chang UK, Chao ST, Faruqi S, Ghia AJ, Redmond KJ, Soltys SG, Liu MC (2020) International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT). Radiother Oncol 145:21–29. https://​doi.​org/​10.​1016/​j.​radonc.​2019.​11.​026CrossRefPubMed
20.
Zurück zum Zitat World Health Organization (2018) WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva World Health Organization (2018) WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva
22.
Zurück zum Zitat Nalichowski A, Kaufman I, Gallo J, Bossenberger T, Solberg T, Ramirez E, Yan Y, Fredrick J, Bichay T, Mayville A, Burmeister J (2017) Single fraction radiosurgery/stereotactic body radiation therapy (SBRT) for spine metastasis: a dosimetric comparison of multiple delivery platforms. J Appl Clin Med Phys 18:164–169. https://doi.org/10.1002/acm2.12022CrossRefPubMed Nalichowski A, Kaufman I, Gallo J, Bossenberger T, Solberg T, Ramirez E, Yan Y, Fredrick J, Bichay T, Mayville A, Burmeister J (2017) Single fraction radiosurgery/stereotactic body radiation therapy (SBRT) for spine metastasis: a dosimetric comparison of multiple delivery platforms. J Appl Clin Med Phys 18:164–169. https://​doi.​org/​10.​1002/​acm2.​12022CrossRefPubMed
Metadaten
Titel
Frequency of and risk factors associated with local recurrence after spinal stereotactic body radiation therapy without surgery
verfasst von
Hidetoshi Shimizu
Yutaro Koide
Shoichi Haimoto
Takahiro Aoyama
Hiroyuki Tachibana
Shingo Hashimoto
Tohru Iwata
Tomoki Kitagawa
Takeshi Kodaira
Publikationsdatum
24.07.2024
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-024-04755-7

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Ehe schützt nicht vor Demenz

  • 25.04.2025
  • Demenz
  • Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.